The Rose Sheet’s coverage of FDA’s warning letter crackdown and data sharing produced some of its most-read stories of 2016, based on online analytics. Legislative proposals and cosmetic safety issues in the US mainstream factored in the agency’s transparency work, a situation that may not repeat in the new year. FDA’s focus on anti-aging claims yielded an unprecedented number of warning letters to cosmetic manufacturers in 2016, a year in which the agency also provided an unusually high level of visibility into its cosmetics regulatory program and the safety data at its disposal.
展开▼
